Alectinib HCl (ALECENSA, AF-802, CH-5424802, RO-5424802)

Alias: AF802 HCl; RO5424802 HCl; RO 5424802 HCl; RO-5424802 HCl; AF 802 HCl; AF-802 HCl; CH5424802 HCl; CH 5424802 HCl; CH-5424802 HCl; trade name: Alecensa
Cat No.:V0070 Purity: ≥98%
Alectinib HCl (formerly AF802, CH5424802 or RO5424802; trade name ALECENSA) is a potent, selective, and orally bioavailable inhibitor of ALK (anaplastic lymphoma kinase) tyrosine kinase with IC50 value of 1.9 nM in cell-free assays.
Alectinib HCl (ALECENSA, AF-802, CH-5424802, RO-5424802) Chemical Structure CAS No.: 1256589-74-8
Product category: ALK
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
10mg
25mg
50mg
100mg
250mg
500mg
Other Sizes

Other Forms of Alectinib HCl (ALECENSA, AF-802, CH-5424802, RO-5424802):

  • Alectinib (AF-802, CH-5424802, RO-5424802, Alecensa)
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description

Alectinib HCl (formerly AF802, CH5424802 or RO5424802; trade name ALECENSA) is a potent, selective, and orally bioavailable inhibitor of ALK (anaplastic lymphoma kinase) tyrosine kinase with IC50 value of 1.9 nM in cell-free assays. The Food and Drug Administration (FDA) approved alelectinib for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC) due to its possible anticancer activity.

Biological Activity I Assay Protocols (From Reference)
Targets
ALK (IC50 = 1.9 nM); ALKF1174L (IC50 = 1 nM); ALKR1275Q (IC50 = 3.5 nM); ALK (Kd = 2.4 nM)
ln Vitro

Alectinib exhibits higher selectivity for ALK than for several other serine/tyrosine kinases, and it inhibits ALK with an IC50 value of 1.9 nmol/L. With an IC50 of 1.56 nmol/L, it also inhibits the ALK gatekeeper mutation L1196M. With crizotinib-resistant ALK mutations L1196M, F1174L, R1275Q, and C1156Y, alelectinib is effective. Alectinib inhibits cell proliferation in ALK-positive cell lines of KARPAS-299 (lymphoma), NB-1 (neuroblastoma), and NCI-H2228 (lung cancer) with IC50 values of 3, 4.5, and 53 nmol/L, respectively[1].

ln Vivo
Alectinib dose-dependently inhibits EML4-ALK positive NCI-H2228 xenograft model at doses ranging from 2 to 20 mg/kg p.o., q.d. Significant efficacy is also attained in tumors driven by EML4-ALK L1196M[1]. When it comes to cancers with ALK gene mutations, it exhibits antitumor activity[2].
Enzyme Assay
The ability of each kinase, with the exception of MEK1 and Raf-1, to phosphorylate different substrate peptides in the presence of CH5424802 is assessed by means of the time-resolved fluorescence resonance energy transfer (TR-FRET) assay or the fluorescence polarization (FP) assay. By quantitatively analyzing the phosphorylation of a substrate peptide by a recombinant ERK2 protein in the presence of CH5424802, the inhibitory activity against MEK1 is assessed. The kinases' capacity to phosphorylate MEK1 in the presence of CH5424802 is used to measure their inhibitory activity against Raf-1.
Cell Assay
In 96-well plates, cells (NSCLC, A549, and HCC827) are seeded overnight, and then different concentrations of CH5424802 are incubated for the specified amount of time. In order to perform the spheroid cell growth inhibition assay, cells are first seeded onto spheroid plates, incubated for a full night, and then exposed to the compound for the prescribed duration of time. The Luminescent Cell Viability Assay determines the number of viable cells. The Caspase-Glo 3/7 Assay Kit is used to assess the Caspase-3/7 assay.
Animal Protocol
SCID or nude mice bearing NCI-H2228 cells
0.2 mg/kg, 0.6 mg/kg, 2 mg/kg, 6 mg/kg, 20 mg/kg
Oral administration; once daily; for 11 days
References

[1]. Acta Pharm Sin B . 2015 Jan;5(1):34-7.

[2]. Cancer Lett . 2014 Sep 1;351(2):215-21.

[3]. Exp Mol Med. 2017 Mar; 49(3): e303.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C30H34N4O2.HCL
Molecular Weight
519.08
Exact Mass
518.2448541
Elemental Analysis
C, 69.42; H, 6.80; Cl, 6.83; N, 10.79; O, 6.16
CAS #
1256589-74-8
Appearance
Solid powder
SMILES
CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C.Cl
InChi Key
GYABBVHSRIHYJR-UHFFFAOYSA-N
InChi Code
InChI=1S/C30H34N4O2.ClH/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29;/h5-6,15-17,21,32H,4,7-14H2,1-3H3;1H
Chemical Name
9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile;hydrochloride
Synonyms
AF802 HCl; RO5424802 HCl; RO 5424802 HCl; RO-5424802 HCl; AF 802 HCl; AF-802 HCl; CH5424802 HCl; CH 5424802 HCl; CH-5424802 HCl; trade name: Alecensa
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~2 mg/mL
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
30% PEG400+0.5% Tween80+5% propylene glycol: 30mg/mL
 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.9265 mL 9.6324 mL 19.2649 mL
5 mM 0.3853 mL 1.9265 mL 3.8530 mL
10 mM 0.1926 mL 0.9632 mL 1.9265 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05987956 Not yet recruiting Drug: Alectinib - Usual
Drug: Alectinib - Study
Non-small Cell Lung Cancer Han Xu, M.D., Ph.D., FAPCR,
Sponsor-Investigator, IRB Chair
November 8, 2023 Phase 2
Phase 3
NCT01801111 Completed Drug: Erlotinib
Drug: Alectinib
Non-Small-Cell Lung Carcinoma Hoffmann-La Roche June 20, 2013 Phase 1
Phase 2
NCT02013219 Completed Drug: Alectinib
Drug: Erlotinib
Non-Small Cell Lung Cancer Hoffmann-La Roche April 3, 2014 Phase 1
Biological Data
  • Alectinib HCl

    The structure and cytotoxicity of alectinib.. 2017 Mar; 49(3): e303.

  • Alectinib HCl

    Potentiation of the anticancer effects of paclitaxel by alectinib in the KBv200 cell xenograft nude mice model. The tumor growth curve was drawn to monitor the tumor volume with time after implantation. The data shown are expressed as the mean±s.d. of the tumor volume for each group (n=9) (a).. 2017 Mar; 49(3): e303.

  • Alectinib HCl

    Effect of alectinib on the intracellular accumulations of DOX and Rho 123 in MDR cells and in their parental sensitive cells.. 2017 Mar; 49(3): e303.

Contact Us